When tested in patients with type 2 diabetes, Efendic had noticed that they lost more weight than when just on insulin (Phelan
The jump from 10 mg to 15 mg produced only about one additional percentage point of weight loss for some participants, which means many people find their optimal balance between results and tolerability somewhere in the 7.5 to 12.5 mg range
External resources SURPASS-CVOT: Cardiovascular Outcomes with Tirzepatide (New England Journal of Medicine) SYNERGY-NASH Trial Results (American College of Gastroenterology) SURMOUNT-OSA: Tirzepatide for Sleep Apnea and Obesity (PubMed Central) In case I do not see you, good afternoon, good evening, and good night
Competitive Landscape: The GLP-1 War Between Novo Nordisk and Eli Lilly Novo Nordisk and Eli Lilly continue to dominate both commercial sales and visibility across AI search platforms
10.1016/j.jare.2023.07.002 19 ChelakkotC.GhimJ.RyuS
Many buy the appetite-suppressants privately which could one day be in pill form